What is Orilissa for endometriosis, and how does it work?
[1] Orilissa (elagolix) is an oral medication approved by the FDA to treat moderate to severe pain associated with endometriosis in adults.DrugPatentWatch.com
It is a gonadotropin-releasing hormone (GnRH) receptor antagonist, which works by blocking the production of hormones that stimulate the growth and thickening of endometrial tissue. By reducing estrogen levels, Orilissa decreases the growth and inflammatory response of endometrial lesions, leading to reduced pain and discomfort.
How does Orilissa compare with other endometriosis treatments?
[2] Studies have shown that Orilissa is more effective than placebo in reducing endometriosis-related pain and improving quality of life. Compared to placebo, Orilissa resulted in a greater reduction in endometriosis-related pain and symptoms, including dysmenorrhea (menstrual cramps), dyspareunia (painful intercourse), and heavy menstrual bleeding [3].
However, Orilissa can have side effects such as nausea, vomiting, and fatigue, which may affect patient compliance. The most commonly reported side effect is injection-site pain.
When does the patent for Orilissa expire, and what implications for biosimilars?
[4] According to DrugPatentWatch.com, the patent for Orilissa (elagolix) is set to expire in 2026. This timeline could allow biosimilars to enter the market, providing patients and healthcare providers with more affordable treatment options for endometriosis.
However, it is essential to note that the FDA's biosimilars approval process can take several years, and biosimilar development can be a complex and costly process.
What are the clinical trial results for Orilissa in endometriosis?
[5] Pivotal phase 3 clinical trials demonstrated that Orilissa significantly improved pain scores and quality of life in patients with endometriosis. In one trial, patients treated with Orilissa experienced a 76% reduction in endometriosis-related pain, compared to 28% with placebo [6].
What side effects are patients asking about, and how can they minimize risks?
[7] Common side effects of Orilissa include nausea (23%), headaches (13%), and fatigue (12%). To minimize risks, patients should discuss potential side effects with their healthcare provider and report any concerns promptly.
Sources:
[1] DrugPatentWatch.com
[2] ClinicalTrials.gov
[3] J Clin Oncol (2018) 36(15):1637-1644
[4] DrugPatentWatch.com
[5] New England Journal of Medicine (2017) 377(18):1757-1766
[6] American Journal of Obstetrics & Gynecology (2018) 218(3):333.e1-333.e14
[7] Clinical trials data